PRODUCT LITERATURE

Cardiac Safety and Clinical Efficacy of High Dose Domperidone for Long-Term Treatment of Gastroparesis

---

Domperidone (D), a dopamine 2 receptor antagonist, is an effective anti-emetic that acts at the chemoreceptor trigger zone and only minimally crosses the blood brain barrier while also exerting prokinetic effects on the stomach and proximal small bowel. D is not approved in the USA. Recommended dosing worldwide is 30 mg/day and due to scattered reports of cardio toxicity
ECG monitoring is recommended. Our goal was to explore the cardiac safety and clinical efficacy of long-term use of D, titrated as high as 120 mg/day, in patients not responding or unable to tolerate other therapies for gastroparesis (GP).

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Vometa
Domperidone

Specific Detail Info

American Journal of GASTROENTEROLOGY 2019

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment